33620 Results

People

  1. Ladanyi
    Ladanyi
  2. Giralt
    Giralt
  3. Motzer
    Motzer
  4. Reuter
    Reuter
  5. Perales
    Perales
  6. Scher
    Scher
  7. Zelenetz
    Zelenetz
  8. Berger
    Berger
  9. Al-Ahmadie
    Al-Ahmadie
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)
  7. Department of Pathology and Laboratory Medicine (5172)
  8. Surgery (4871)
  9. Sloan Kettering Institute Faculty (3826)
  10. Sloan Kettering Institute Postdocs (3612)
  1. "Meeting abstract"
Formats
  1. Meeting Abstract (33620)
Groups
  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)

More Groups

People
  1. Marc Ladanyi (641)
  2. Sergio Giralt (632)
  3. Robert Motzer (574)
  4. Victor Reuter (568)
  5. Miguel-Angel Perales (482)
  6. Howard Scher (463)

More People

Years
  1. 2025 (295)
  2. 2024 (1694)
  3. 2023 (1954)
  4. 2022 (2196)
  5. 2021 (1731)
  6. 2020 (1901)

More Years

Publications
  1. Journal of Clinical Oncology (6252)
  2. Blood (3939)
  3. Laboratory Investigation (1846)
  4. Cancer Research (1822)
  5. International Journal of Radiation Oncology, Biology, Physics (1643)
  6. Modern Pathology (1494)

More Publications

Publishers
  1. American Society of Clinical Oncology (6251)
  2. Elsevier Inc. (4694)
  3. American Society of Hematology (3939)
  4. American Association for Cancer Research (3045)
  5. Nature Publishing Group (2151)
  6. Oxford University Press (2096)

More Publishers

Results (33620)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Implementation of a palliative care screening tool to improve early referral rate in the ICU
    Meeting Abstract

    Bradford, L.; Aguilar, A.; Ash, P.; Carr, N.; Nicastro, O.; Yohannes-Tomicich, J.
    Critical Care Medicine (2025)

    Fulltext@MSK | Save
  • Gastrointestinal bleeding in checkpoint inhibitor therapy for metastatic lung cancer
    Meeting Abstract

    Fowler, C.; Nasser, J.; Sekaran, K.; Chism, L.; Pastores, S.
    Critical Care Medicine (2025)

    Fulltext@MSK | Save
  • Plex to the rescue in triple M syndrome's myasthenic crisis
    Meeting Abstract

    Sajja, P.; Onkaramurthy, N. J.; Dulu, A.; Pastores, S.
    Critical Care Medicine (2025)

    Fulltext@MSK | Save
  • Recurrent pericardial effusion with tamponade physiology from tense ascites in a cancer patient
    Meeting Abstract

    Huang, K.; Pastores, S.
    Critical Care Medicine (2025)

    Fulltext@MSK | Save
  • An emerging culprit of diffuse alveolar hemorrhage: Irinotecan therapy
    Meeting Abstract

    Onkaramurthy, N. J.; Imran, S.; Pastores, S.
    Critical Care Medicine (2025)

    Fulltext@MSK | Save
  • Defying diagnostic odds: Diagnosing neuroleptic malignant syndrome (NMS) amidst confounders
    Meeting Abstract

    Aguilar, A.; Nicastro, O.; Yohannes-Tomicich, J.; Ash, P.; Bradford, L.; Carr, N.
    Critical Care Medicine (2025)

    Fulltext@MSK | Save
  • Artificial intelligence and venous thromboembolism: Talking to the experts
    Meeting Abstract

    Gupta, A.; Lam, B. D.; Zerbey, S.; Robertson, W.; Rosovsky, R. P.; Lake, L.; Dodge, L.; Adamski, A.; Reyes, N.; Abe, K.; more...
    American Journal of Hematology (2025)

    Fulltext@MSK | Save
  • INSIGHT: A phase 3, randomized, open-label study of ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib with KIT exon 11 + 17/18 mutations
    Meeting Abstract

    Heinrich, M. C.; Blay, J. V.; Chi, P.; Jones, R. L.; Serrano, C.; Somaiah, N.; Gelderblom, H.; Zalcberg, J. R.; Reichmann, W.; Sprott, K.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • MOONRAY-01, a phase 1 study of LY3962673, a potent, orally bioavailable, and selective KRAS G12D inhibitor in KRAS G12D -mutant solid tumors
    Meeting Abstract

    Lakhani, N. J.; Melisi, D.; Subbiah, V.; Ammakkanavar, N. R.; O'Reilly, E. M.; Cassier, P. A.; Wainberg, Z. A.; Duffy, A. G.; Patnaik, A.; Fujiwara, Y.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Randomized phase II trial of olaparib + pembrolizumab vs olaparib alone as maintenance therapy in patients with metastatic pancreatic cancer with germline BRCA1 or BRCA2 mutations: SWOG S2001 NCT04548752
    Meeting Abstract

    Chung, V.; Guthrie, K. A.; Pishvaian, M. J.; Lowy, A. M.; Sohal, D.; Reiss, K. A.; Sanford, N. N.; Allegra, C.; Colby, S.; O'Reilly, E. M.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save